Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Kunstfeld

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 20, 2023
Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022G Pellacani, T Schlesinger, N Bhatia, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 20, 2023
Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022G Pellacani, T Schlesinger, N Bhatia, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Pageof 2